News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,310 Results
Type
Article (41129)
Company Profile (275)
Press Release (682894)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (205062)
Career Advice (2055)
Deals (35579)
Drug Delivery (114)
Drug Development (81516)
Employer Resources (173)
FDA (16445)
Job Trends (14974)
News (347024)
Policy (32786)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2580)
Accelerated approval (38)
Adcomms (25)
Allergies (149)
Alliances (49673)
ALS (176)
Alzheimer's disease (1685)
Antibody-drug conjugate (ADC) (329)
Approvals (16722)
Artificial intelligence (541)
Autoimmune disease (164)
Automation (44)
Bankruptcy (361)
Best Places to Work (11653)
BIOSECURE Act (20)
Biosimilars (194)
Biotechnology (181)
Bladder cancer (164)
Brain cancer (59)
Breast cancer (655)
Cancer (4967)
Cardiovascular disease (410)
Career advice (1732)
Career pathing (37)
CAR-T (288)
CDC (49)
Celiac Disease (2)
Cell therapy (762)
Cervical cancer (37)
Clinical research (69821)
Collaboration (1758)
Company closure (4)
Compensation (1183)
Complete response letters (58)
COVID-19 (2722)
CRISPR (95)
C-suite (882)
Cystic fibrosis (143)
Data (6432)
Decentralized trials (2)
Denatured (25)
Depression (136)
Diabetes (510)
Diagnostics (6748)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (260)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (90506)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117895)
Executive appointments (991)
FDA (19644)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (24)
Funding (1510)
Gene editing (203)
Generative AI (44)
Gene therapy (615)
GLP-1 (979)
Government (4679)
Grass and pollen (6)
Guidances (385)
Healthcare (18926)
HIV (68)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (256)
Immuno-oncology (65)
Indications (127)
Infectious disease (3006)
Inflammatory bowel disease (199)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (258)
Interviews (326)
IPO (16666)
IRA (50)
Job creations (3653)
Job search strategy (1444)
JPM (57)
Kidney cancer (18)
Labor market (87)
Layoffs (549)
Leadership (33)
Legal (7960)
Liver cancer (93)
Longevity (17)
Lung cancer (669)
Lymphoma (386)
Machine learning (45)
Management (59)
Manufacturing (823)
MASH (166)
Medical device (13827)
Medtech (13887)
Mergers & acquisitions (20001)
Metabolic disorders (1292)
mRNA (159)
Multiple sclerosis (166)
NASH (16)
Neurodegenerative disease (332)
Neuropsychiatric disorders (89)
Neuroscience (2958)
Neurotech (1)
NextGen: Class of 2026 (6537)
Non-profit (4525)
Now hiring (69)
Obesity (607)
Opinion (266)
Ovarian cancer (169)
Pain (207)
Pancreatic cancer (237)
Parkinson's disease (291)
Partnered (33)
Patents (515)
Patient recruitment (519)
Peanut (59)
People (59170)
Pharmaceutical (62)
Pharmacy benefit managers (30)
Phase 1 (21782)
Phase 2 (30729)
Phase 3 (22886)
Pipeline (5772)
Policy (295)
Postmarket research (2565)
Preclinical (9229)
Press Release (64)
Prostate cancer (253)
Psychedelics (48)
Radiopharmaceuticals (289)
Rare diseases (883)
Real estate (5970)
Recruiting (70)
Regulatory (24670)
Reports (53)
Research institute (2401)
Resumes & cover letters (359)
Rett syndrome (29)
RNA editing (16)
RSV (81)
Schizophrenia (150)
Series A (251)
Series B (193)
Service/supplier (11)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3626)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (84)
The Weekly (55)
Vaccines (1018)
Venture capital (89)
Weight loss (389)
Women's health (98)
Worklife (19)
Date
Today (109)
Last 7 days (870)
Last 30 days (2846)
Last 365 days (29974)
2026 (4861)
2025 (30232)
2024 (35268)
2023 (40137)
2022 (51253)
2021 (55795)
2020 (54159)
2019 (46611)
2018 (35079)
2017 (32160)
2016 (31541)
2015 (37618)
2014 (31379)
2013 (26394)
2012 (28612)
2011 (29307)
2010 (27382)
Location
Africa (737)
Alabama (86)
Alaska (7)
Arizona (315)
Arkansas (13)
Asia (39404)
Australia (6448)
California (11623)
Canada (3354)
China (1124)
Colorado (489)
Connecticut (490)
Delaware (343)
Europe (85013)
Florida (1746)
Georgia (370)
Hawaii (3)
Idaho (61)
Illinois (886)
India (70)
Indiana (536)
Iowa (22)
Japan (443)
Kansas (128)
Kentucky (42)
Louisiana (27)
Maine (72)
Maryland (1419)
Massachusetts (8304)
Michigan (335)
Minnesota (637)
Mississippi (6)
Missouri (129)
Montana (32)
Nebraska (29)
Nevada (125)
New Hampshire (81)
New Jersey (3082)
New Mexico (28)
New York (3056)
North Carolina (1487)
North Dakota (8)
Northern California (5706)
Ohio (346)
Oklahoma (21)
Oregon (41)
Pennsylvania (2361)
Puerto Rico (24)
Rhode Island (49)
South America (1114)
South Carolina (68)
South Dakota (1)
Southern California (4532)
Tennessee (180)
Texas (1789)
United States (41147)
Utah (350)
Vermont (1)
Virginia (270)
Washington D.C. (82)
Washington State (938)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
724,310 Results for "sab biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SAB BIO to Participate in Upcoming February 2026 Investor Conferences
February 5, 2026
·
1 min read
Press Releases
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
December 19, 2025
·
6 min read
Press Releases
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
December 8, 2025
·
5 min read
Press Releases
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Press Releases
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
January 8, 2026
·
7 min read
Press Releases
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
December 18, 2025
·
7 min read
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics today announced its new name, SAB BIO, and visual identity to more closely align with its mission to treat and prevent immune and autoimmune disorders with the use of its unique immunotherapy platform.
June 20, 2024
·
5 min read
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA disclosed that SAB has completed dosing the third cohort for SAB-142.
April 16, 2024
·
5 min read
Press Releases
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
November 5, 2025
·
6 min read
Press Releases
SAB BIO to Participate in Upcoming Investor Conferences - November 4, 2025
November 5, 2025
·
1 min read
1 of 72,431
Next
